Chemexpress(SH:688131) Ge Long Hui A P P·2026-02-27 12:54Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a strong performance for the fiscal year 2025, with significant growth in revenue and net profit, indicating a robust business strategy focused on international expansion and innovation [1] Financial Performance - The company achieved total operating revenue of 2.868 billion yuan, representing a year-on-year increase of 26.35% [1] - The net profit attributable to shareholders reached 248 million yuan, up 22.91% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 252 million yuan, reflecting a substantial year-on-year growth of 40.82% [1] Business Strategy - The company strengthened its brand and overseas business team, actively developing international partnerships and expanding into overseas markets [1] - Emphasis was placed on innovation and quality management, leading to strong growth in the life science reagent business, which saw an increased revenue share compared to 2024 [1] - The high gross margin of the life science reagent business is attributed to its focus on cutting-edge scientific research and new drug development, providing diverse product and technical support to clients in the early stages of drug discovery [1]